First-Line Treatment of Angioimmunoblastic T-Cell Lymphoma

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive nodal T-cell malignancy. Outcomes with current therapy remain poor, and first-line systemic treatment is initiated at diagnosis. A structured, evidence-based approach guides the initial management of these patients.

First-Line Treatment Approach

Initial management centers on a CHOP-based chemotherapy regimen. In responding patients with advanced or high-risk disease, a consolidative transplantation strategy may be considered alongside chemotherapy — full eligibility criteria, sequencing, and evidence grades are detailed in the structured protocol.

The complete regimen, including all treatment options and clinical decision points, is available in the full protocol below.